SPGL008 Monotherapy for Advanced Malignant Tumors Treatment

This study focuses on testing a new treatment called SPGL-008 for patients with advanced malignant tumors. Malignant tumors are a form of cancer that can spread to other parts of the body. The goal is to find out if SPGL-008 is safe and can be tolerated by patients, as well as to see if it shows any early signs of effectiveness against the tumors. This study is important because it could lead to new treatment options for patients with these severe forms of cancer, who often have limited choices. Participants in the study are divided into two groups. One group receives SPGL-008 through a vein, which is called intravenous administration, while the other group receives it under the skin, known as subcutaneous administration. The study uses a method called dose-escalation, meaning the amount of SPGL-008 given is gradually increased to determine the safest and most effective dose. Researchers will closely monitor participants to assess how well they tolerate the medication and to observe any potential benefits or side effects. The results from this study will help understand if SPGL-008 could be a viable treatment option in the future.